A Phase 1b/2a Study in Participants With Early Stage COVID-19 to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation
Latest Information Update: 04 Mar 2022
At a glance
- Drugs Remdesivir (Primary)
- Indications SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 08 Apr 2021 Status changed from active, no longer recruiting to completed.
- 08 Mar 2021 Status changed from recruiting to active, no longer recruiting.
- 15 Jan 2021 Planned number of patients changed from 282 to 152.